Skip to main content

Table 2 Risk of GORD and PPI use among hormone replacement therapy users: simple regression

From: Hormone replacement therapy is associated with gastro-oesophageal reflux disease: a retrospective cohort study

   All hormone users Oestrogen-only users Tibolone users Combined HRT users Progestogen users
No. of hormone users Unmatched cohort 22101 9137 7678 1539 3747
  Matched 1 cohort 2777 950 167 1190 470
GORD OR (95%CI) p Unmatched cohort 1.23 (1.18–1.27) <0.001 1.36 (1.29–1.43) <0.001 1.26 (1.23–1.51) <0.001 1.15 (1.09–1.20) <0.001 1.11 (1.04–1.20) 0.040
  Matched cohort 1.29 (1.12–1.48) <0.001 1.59 (1.27–2.0) <0.001 1.14 (1.06–1.22) <0.001 1.14 (0.92–1.43) 0.234 1.15 (1.06–1.23) <0.001
PPI2 OR (95%CI) 3p Unmatched cohort 1.38 (1.19–1.60) <0.001 1.46 (1.16–1.84) 0.001 1.52 (0.92–2.50) 0.100 1.41 (1.10–1.80) 0.006 1.06 (0.71–1.59) 0.760
  Matched cohort 1.30 (1.15–1.52) 0.001 1.42 (1.10–1.84) 0.007 1.38 (0.48–3.95) 0.549 1.21 (0.95–1.54) 0.121 1.18 (0.72–1.95) 0.512
  1. 1. Uses and non-users were matched according to calendar year, age at menopause, socio-economic status of GP practice, and date closest to menopause.
  2. 2. Ever PPI use within study window.
  3. 3. P-values: comparison of binary variables by adjusted χ 2 test; continuous variables by Student’s t-test; multiple category variables by χ 2 test adjusted for trend.
\